# OnCo record paper-train-2-lancet-oncol-2018 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-train-2-lancet-oncol-2018/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-train-2-lancet-oncol-2018" ;
  schema:name "TRAIN-2: neoadjuvant chemotherapy with or without anthracyclines alongside dual HER2 blockade"@en ;
  schema:description "Leaving out anthracyclines from neoadjuvant chemotherapy made no difference to how many HER2-positive breast cancers disappeared completely when trastuzumab and pertuzumab were given, so the heart-toxic drugs can be dropped."@en ;
  schema:url <https://onco.cc/key-papers/paper-train-2-lancet-oncol-2018/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S1470-2045(18)30570-9>, <https://pubmed.ncbi.nlm.nih.gov/30413379/> ;
  schema:sameAs <https://doi.org/10.1016/S1470-2045(18)30570-9> ;
  schema:datePublished "2018"^^xsd:gYear ;
  schema:author "van Ramshorst MS, van der Voort A, van Werkhoven ED, et al." ;
  onco:cancers <https://onco.cc/cancers/her2-positive-early-breast-cancer/> ;
  onco:trials <https://onco.cc/trials/train-2/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .